A new way was to answer migraine says, clinical trials.
The new route found led a way to decrease the rate of migraine to half. King’s College Hospital calls it to be a great deal. The route was found such that antibodies that are created will go, change the chemical activity of the human brain. The founders say that one in every seven people were suffering from migraine and is prevalent in women than that of men.
The head ache that suffers a person more than fifteen days are called chronic. The Migraine Trust says that more than one lakh ninety thousand people are affected from migraine every year in the UK.
It has been found that a chemical namely, calcitonin is responsible for pain and sensitivity to both light and sound. The antibodies are to go and change this effect to curb the migraine which has been a great success.
The chemical is also called CGRP, four of the major companies are working neck and neck to find out the solution against the chemical. Clinical trials that are published in England based on the making up of antibodies was a great deal.
955 patients have been studied with a new antibody namely, erenumab that was found by Novartis. A study found that the migraine fell to half that is it used to be 8 days a month on average which is not on par with the current rate.
Patients suffering from chronic migraine have been tested with another antibody namely, fremanezumab that was found by Teva. It was experimented on over 1,130 people approximately.
Erenumab trail leader Professor Peter Goadsby told BBC that it was a huge deal because it offered an advance in understanding the disorder and a designer migraine treatment. It reduced the frequency and severity of headaches. Those patients would have parts of their life back and society would have these people back functioning.
There came up new ways to curb the migraine other than the antibodies. Some of them are epilepsy, botox etc. Simon Evans, the chief executive of migraine action said that the pills didn’t work on everybody and had a lot of side effects which prove the antibodies to be the better.
He says, “Some doctors give patients a choice of being angry or fat-and-dosey and the drug they give them depends on their answer.” The actual path the work have been going on is to modify and make perfect antibodies against migraine. Here is a problem with antibodies, they are costly.
Dr Andy Dowson, a headache service runner says, “I am really enthusiastic we have something new that’s coming, but we need to know cost, who will respond and a lot more detail as we go down the line.”
The hope is to find out ways to treat both chronic and non-chronic migraines effectively at low costs and without side effects.